{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:50:14Z","timestamp":1792601414040,"version":"4.5.0"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>T cell lymphomas are a heterogenous group with varying biological and clinical features that tend to have poor outcomes with a few exceptions. They account for 10-15% of all non-Hodgkin lymphomas (NHL), and 20% of aggressive NHL. There has been little change in the overall prognosis of T cell lymphomas over the last 2 decades. Most subtypes carry an inferior prognosis when compared to the B cell lymphomas, with a 5-year OS of 30%. Gene expression profiling and other molecular techniques has enabled a deeper understanding of these differences in the various subtypes as reflected in the latest 5th WHO and ICC classification of T cell lymphomas. It is becoming increasingly clear that therapeutic approaches that target specific cellular pathways are needed to improve the clinical outcomes of T cell lymphomas. This review will focus on nodal T cell lymphomas and describe novel treatments and their applicability to the various subtypes.<\/jats:p>","DOI":"10.3389\/fonc.2023.1150715","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T05:39:44Z","timestamp":1682660384000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Challenges in nodal peripheral T-cell lymphomas: from biological advances to clinical applicability"],"prefix":"10.3389","volume":"13","author":[{"given":"Jasmine","family":"Zain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avyakta","family":"Kallam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"B1","article-title":"Who classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017","journal-title":"Int Agency For Res On Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of hematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh409","article-title":"Towards understanding the peripheral T-cell lymphomas","volume":"15","author":"Armitage","year":"2004","journal-title":"Ann Of Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal propel study","volume":"29","author":"O'connor","year":"2011","journal-title":"J Of Clin Oncol Off J Of Am Soc Of Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for Cd30-positive peripheral T-cell lymphoma (Echelon-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13222","article-title":"A phase ii trial of belinostat (Pxd 101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br J Of Haematology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14477","article-title":"Survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-cell lymphoma project. international peripheral T-cell and natural Killer\/T-cell lymphoma study: Patholegy findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncck"},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-1-62703-170-7_2","article-title":"Epidemiology and prognosis of T-cell lymphoma","author":"Wang","year":"2013","journal-title":"T-Cell Lymphomas. Springer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.beha.2009.05.001","article-title":"Gene expression profiling in lymphoma diagnosis and management","volume":"22","author":"Iqbal","year":"2009","journal-title":"Best Pract Res Clin Haematology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00428-022-03412-6","article-title":"Classification and diagnostic evaluation of nodal T-and nk-cell lymphomas","volume":"482","author":"Feldman","year":"2022","journal-title":"Virchows Archiv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24203","article-title":"A three-signal model of T-cell lymphoma pathogenesis","volume":"91","author":"Wilcox","year":"2016","journal-title":"Am J Of Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev-pathol-020117-043821","article-title":"Pathogenesis of peripheral T cell lymphoma","volume":"13","author":"Pizzi","year":"2018","journal-title":"Annu Rev Of Pathology: Mech Of Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral T cell lymphomas: From the bench to the clinic","volume":"20","author":"Fiore","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1955344","article-title":"The expression of Cd30 and its clinic-pathologic significance in peripheral T cell lymphoma","volume":"14","author":"Karube","year":"2021","journal-title":"Expert Rev Of Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma\u2013nos by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.5611","article-title":"Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: Results of a phase iii diagnostic accuracy study","volume":"31","author":"Piccaluga","year":"2013","journal-title":"J Of Clin Oncol Off J Of Am Soc Of Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0279-8","article-title":"Whole exome sequencing reveals mutations in Fat1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified","volume":"33","author":"Laginestra","year":"2020","journal-title":"Modern Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent Tet2 mutations in peripheral T-cell lymphomas correlate with tfh-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-644591","article-title":"Idh2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-017-0047-2","article-title":"Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways","volume":"8","author":"Willemsen","year":"2018","journal-title":"Blood Cancer J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.yamp.2022.05.002","article-title":"Molecular advances in nodal peripheral T-cell lymphoma","volume":"5","author":"Hafeez","year":"2022","journal-title":"Adv In Mol Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (Sgn-35) in patients with relapsed or refractory systemic anaplastic Large-cell lymphoma: Results of a phase ii study","volume":"30","author":"Pro","year":"2012","journal-title":"J Of Clin Oncol Off J Of Am Soc Of Clin Oncol"},{"key":"B28","article-title":"Prognostic significance of anaplastic lymphoma kinase (Alk) protein expression in adults with anaplastic Large cell lymphoma","volume":"93","author":"Gascoyne","year":"1999","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.8195","article-title":"International assessment of event-free survival At 24 months and subsequent survival in peripheral T-cell lymphoma","volume":"35","author":"Maurer","year":"2017","journal-title":"J Of Clin Oncol Off J Of Am Soc Of Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270","article-title":"Alk\u2013 anaplastic Large-cell lymphoma is clinically and immunophenotypically different from both alk alcl and peripheral T-cell lymphoma, not otherwise specified: Report from the international peripheral T-cell lymphoma project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-717793","article-title":"Nucleophosmin-anaplastic lymphoma kinase: The ultimate oncogene and therapeutic target","volume":"129","author":"Werner","year":"2017","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, alk, to a nucleolar protein gene, npm, in non-hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Sci (New York N.Y.)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01093-1","article-title":"Stat3 and Tp53 mutations associate with poor prognosis in anaplastic Large cell lymphoma","volume":"35","author":"Lobello","year":"2021","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238766","article-title":"Whole exome sequencing reveals Notch1 mutations in anaplastic Large cell lymphoma and points to notch both as a key pathway and a potential therapeutic target","volume":"106","author":"Larose","year":"2021","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571091","article-title":"Alk-negative anaplastic Large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-838524","article-title":"Molecular profiling reveals immunogenic cues in anaplastic Large cell lymphomas with Dusp22 rearrangements","volume":"132","author":"Luchtel","year":"2018","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/PAS.0000000000000500","article-title":"Morphologic features of alk-negative anaplastic Large cell lymphomas with Dusp22 rearrangements","volume":"40","author":"King","year":"2016","journal-title":"Am J Of Surg Pathol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15860","article-title":"Identification of high-risk Dusp22-rearranged alk-negative anaplastic Large cell lymphoma","volume":"186","author":"Hapgood","year":"2019","journal-title":"Br J Of Haematology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/PAS.0000000000001708","article-title":"Jak2 rearrangements are a recurrent alteration in Cd30 systemic T-cell lymphomas with anaplastic morphology","volume":"45","author":"Fitzpatrick","year":"2021","journal-title":"Am J Of Surg Pathol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.7911","article-title":"Breast implant-associated anaplastic Large-cell lymphoma: Long-term follow-up of 60 patients","volume":"32","author":"Miranda","year":"2014","journal-title":"J Of Clin Oncol Off J Of Am Soc Of Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-821868","article-title":"Genetic subtyping of breast implant\u2013associated anaplastic Large cell lymphoma","volume":"132","author":"Oishi","year":"2018","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000002010","article-title":"Bacterial biofilm infection detected in breast implant\u2013associated anaplastic Large-cell lymphoma","volume":"137","author":"Hu","year":"2016","journal-title":"Plast And Reconstructive Surg"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14431","article-title":"Targeted next generation sequencing of breast implant-associated anaplastic Large cell lymphoma reveals mutations in Jak\/Stat signalling pathway genes, Tp53 and Dnmt3a","volume":"180","author":"Di Napoli","year":"2018","journal-title":"Br J Of Haematology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2068-1","article-title":"Clinical features and treatment outcome of Epstein\u2013Barr virus-positive nodal T-cell lymphoma","volume":"104","author":"Jung","year":"2016","journal-title":"Int J Of Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280003","article-title":"Immune pathway upregulation and lower genomic instability distinguish ebv-positive nodal T\/Nk-cell lymphoma from enktl and ptcl-nos","volume":"107","author":"Wai","year":"2022","journal-title":"Haematologica"},{"key":"B46","first-page":"78","article-title":"Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas","volume-title":"Seminars in hematology","author":"Epstein-Peterson","year":"2021"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1111708","article-title":"Tet2 and Dnmt3a mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"New Engl J Of Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"A161","DOI":"10.1093\/ajcp\/138.suppl1.147","article-title":"Ezh2 expression is increased in neoplastic T cells as compared with reactive lymphocytes and differs in different subtypes of T-cell lymphoma","volume":"138","author":"Dhiran","year":"2012","journal-title":"Am J Of Clin Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/hon.14_2879","article-title":"First-In-Human study of the Ezh1 and Ezh2 dual inhibitor valemetostat tosylate (Ds-3201b) in patients with relapsed or refractory non-Hodgkin lymphomas","volume":"39","author":"Ishitsuka","year":"2021","journal-title":"Hematological Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1182\/blood-2021-144676","article-title":"A global phase 2 study of valemetostat tosylate (Valemetostat) in patients with relapsed or refractory (R\/R) peripheral T-cell lymphoma (Ptcl), including R\/R adult T-cell Leukemia\/Lymphoma (Atl)-Valentine-Ptcl01","volume":"138","author":"Foss","year":"2021","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-007-0260-8","article-title":"Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating aurora-a kinase","volume":"86","author":"Park","year":"2008","journal-title":"J Of Mol Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase ii study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Of Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase ii belief (Cln-19) study","volume":"33","author":"O'connor","year":"2015","journal-title":"J Of Clin Oncol Off J Of Am Soc Of Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1182\/blood.V128.22.4164.4164","article-title":"Treatment with hypomethylating agent 5-azacytidine induces sustained response in angioimmunoblastic T cell lymphomas","volume":"128","author":"Delarue","year":"2016","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.07.009","article-title":"Real-world efficacy of 5-azacytidine as salvage chemotherapy for angioimmunoblastic T-cell lymphoma","volume":"22","author":"Yoon","year":"2022","journal-title":"Clin Lymphoma Myeloma And Leukemia"},{"key":"B56","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The combination of duvelisib, a Pi3k-\u0394, \u0393 inhibitor, and romidepsin is highly active in Relapsed\/Refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165165","article-title":"A real world experience of combined treatment with romidepsin and azacitidine in patients with peripheral T-cell lymphoma-a bridge to transplant and an effective salvage for the unfit","volume":"140","author":"Kalac","year":"2022","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136023","article-title":"Multi-center phase ii study of oral azacitidine (Cc-486) plus chop as initial treatment for peripheral T-cell lymphoma (Ptcl)","volume":"136","author":"Ruan","year":"2020","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive Ezh1 and Ezh2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.3390\/cancers14225699","article-title":"Targeting Tet2 as a therapeutic approach for angioimmunoblastic T cell lymphoma","volume":"14","author":"Hu","year":"2022","journal-title":"Cancers"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.644857","article-title":"Biological roles and therapeutic applications of Idh2 mutations in human cancer","volume":"11","author":"Guo","year":"2021","journal-title":"Front In Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1738-8","article-title":"Multistep tumorigenesis in peripheral T cell lymphoma","volume":"102","author":"Sakata-Yanagimoto","year":"2015","journal-title":"Int J Of Hematol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/leu.2017.273","article-title":"Activation of rhoa\u2013Vav1 signaling in angioimmunoblastic T-cell lymphoma","volume":"32","author":"Fujisawa","year":"2018","journal-title":"Leukemia"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16435","article-title":"Evaluation of the Pik3 pathway in peripheral T-cell lymphoma and Nk\/T-cell lymphoma","volume":"189","author":"Huang","year":"2020","journal-title":"Br J Of Haematology"},{"key":"B65","article-title":"Activity of the Pi3k-\u0394, \u0393 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140412","article-title":"Duvelisib in patients with Relapsed\/Refractory peripheral T-cell lymphoma from the phase 2 primo trial: Dose optimization efficacy update and expansion phase initial results","volume":"136","author":"Pro","year":"2020","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169432","article-title":"Duvelisib in patients with Relapsed\/Refractory peripheral T-cell lymphoma from the phase 2 primo trial expansion phase: Impact of prior treatment and expanded safety analysis","author":"Jacobsen","year":"2022","journal-title":"Blood 140(Supplement 1)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.3390\/cancers12082293","article-title":"Phase I\/Ib study of tenalisib (Rp6530), a dual Pi3k \u0394\/\u0393 inhibitor in patients with Relapsed\/Refractory T-cell lymphoma","volume":"12","author":"Huen","year":"2020","journal-title":"Cancers"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/hon.56_2879","article-title":"The combination of duvelisib and romidepsin (Dr) is highly active against Relapsed\/Refractory peripheral T-cell lymphoma with low rates of transaminitis: Final results","volume":"39","author":"Horwitz","year":"2021","journal-title":"Hematological Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1182\/blood-2018-99-112123","article-title":"Durable responses observed with jak inhibition in T-cell lymphomas","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"110331","DOI":"10.1016\/j.cellsig.2022.110331","article-title":"Syk and Zap70 kinases in autoimmunity and lymphoid malignancies","author":"Leveille","year":"2022","journal-title":"Cell Signalling"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1182\/blood-2018-99-119944","article-title":"The novel Syk\/Jak inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in Relapsed\/Refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.10.017","article-title":"Alisertib (Mln8237) an investigational agent suppresses aurora a and b activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-nhl cell lines supporting its importance in ptcl treatment","volume":"37","author":"Qi","year":"2013","journal-title":"Leukemia Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase iii study of alisertib or investigator's choice (Selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma","author":"O'connor","year":"2019","journal-title":"J Of Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29602","article-title":"Fda approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic Large cell lymphoma","author":"Merino","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"Djt378","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase\u2013positive lymphoma patients","volume":"106","author":"Gambacorti Passerini","year":"2014","journal-title":"J Of Natl Cancer Institute"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-617779","article-title":"Ceritinib in patients with advanced anaplastic lymphoma kinase\u2013rearranged anaplastic Large-cell lymphoma","volume":"126","author":"Richly","year":"2015","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27094","article-title":"Crizotinib induces apoptosis and gene expression changes in alk anaplastic Large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes","volume":"65","author":"Hudson","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-013-0232-x","article-title":"Treatment of peripheral T-cell lymphoma: Are we data driven or driving the data","volume":"14","author":"Lunning","year":"2013","journal-title":"Curr Treat Options In Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with Cd30+ peripheral T-cell lymphomas: Results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Of Clin Oncol Off J Of Am Soc Of Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The echelon-2 trial: 5-year results of a randomized, phase iii study of brentuximab vedotin with chemotherapy for Cd30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Of Oncol"},{"key":"B82","first-page":"5179","article-title":"Mogamulizumab monotherapy in the treatment of Relapsed\/Refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma patients in single-institution experience","volume":"130","author":"Murai","year":"2017","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: A randomized phase ii study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Of Haematology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1440-1827.2007.02195.x","article-title":"Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and nk-cell lymphomas: Analysis of 490 cases","volume":"58","author":"Karube","year":"2008","journal-title":"Pathol Int"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: A phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1182\/blood-2018-99-116907","article-title":"Phase I study of yttrium-90 labeled anti-Cd25 (Atac) monoclonal antibody plus beam for autologous hematopoietic cell transplantation (Ahct) in patients with mature T-cell non-Hodgkin lymphoma, the \u201cA-Tac-Beam regimen\u201d","volume":"132","author":"Zain","year":"2018","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.V122.21.1759.1759","article-title":"The serum spectrum of cytokines in patients with Nk\/T-cell lymphoma and its cilincial significance in survival","volume":"122","author":"Cai","year":"2013","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid\u00ae) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The expect trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Of Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1182\/blood-2018-99-114110","article-title":"Phase I\/Ii study of choep plus lenalidomide as initial therapy for patients with stage ii-iv peripheral T-cell lymphoma: Phase ii results","volume":"132","author":"Lunning","year":"2018","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.8521","article-title":"No title. a phase I\/Ii trial of the combination of romidepsin and lenalidomide in patients with Relapsed\/Refractory lymphoma and myeloma: Activity in T-cell lymphoma","volume":"96","author":"Mehta-Shah","year":"2015","journal-title":"Am J Hematol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1182\/blood.V130.Suppl_1.821.821","article-title":"A phase Ib\/Iia trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with Relapsed\/Refractory lymphoma shows complete responses in relapsed and refractory b-and T-cell lymphomas","volume":"130","author":"Mehta-Shah","year":"2017","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia\u2013lymphoma after pd-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"New Engl J Of Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1182\/blood.V128.22.181.181","article-title":"Pembrolizumab for treatment of Relapsed\/Refractory mycosis fungoides and sezary syndrome: Clinical efficacy in a citn multicenter phase 2 study","volume":"128","author":"Khodadoust","year":"2016","journal-title":"Blood"},{"key":"B96","article-title":"Targeted inhibition of Cd47-sirp\u03b1 requires fc-fc\u03b3r interactions to maximize activity in T-cell lymphomas","volume":"134","author":"Jain","year":"2019","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-021-02595-0","article-title":"Car-T cell therapy in T-cell malignancies: Is success a low-hanging fruit","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00295-8","article-title":"A new immunotherapy strategy targeted Cd30 in peripheral T-cell lymphomas: Car-modified T-cell therapy based on Cd30 mab","volume":"29","author":"Wu","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.49","article-title":"Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance","volume":"30","author":"Spinner","year":"2016","journal-title":"Leukemia"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-865527","article-title":"Biomarker-driven strategy for Mcl1 inhibition in T-cell lymphomas","volume":"133","author":"Koch","year":"2019","journal-title":"Blood J Of Am Soc Of Hematol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000562304.50732.0a","article-title":"Ps1002 rhoe, Cxcl12 and Cxcr3 may identify complete responses in acute myeloid leukemia patients treated with tipifarnib","volume":"3","author":"Gualberto","year":"2019","journal-title":"Hemasphere"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/hon.32_2629","article-title":"Tipifarnib in relapsed or refractory angioimmunoblastic T-cell lymphoma (Aitl) and Cxcl12 peripheral T-cell lymphoma (Ptcl): Preliminary results from a phase 2 study","volume":"37","author":"Witzig","year":"2019","journal-title":"Hematological Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1150715\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T05:39:50Z","timestamp":1682660390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1150715\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":102,"alternative-id":["10.3389\/fonc.2023.1150715"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1150715","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"article-number":"1150715"}}